Knowledge Library

DLL3-Related PDX Models

DLL3 related lung cancer PDX models, validated by RNA-Seq and IHC staining

Resource Type: Latest Science, Presentation
Resource Topic: Lead Optimization, Oncology, Tumor Models

VIEW

c-MET Related In Vivo Models

c-Met is a receptor tyrosine kinase, a/k/a hepatocyte growth factor receptor (HGFR). As a type of proto-oncogene, c-Met overexpression, amplification or gene mutation can promote the development of multiple cancer types, including gastric, liver, lung, breast, pancreatic cancer, and glioblastoma (through the stimulation of multiple signaling pathways).  As a result, c-Met is considered a clinically …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Lead Optimization, Oncology, Tumor Models

VIEW

AACR 2023: Integrated platform enables KRAS-targeted drugs discovery

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as …Read More >

Resource Type: Poster
Resource Topic: Biochemical Assays, Biophysical Assays, Cell-based Assays, Hit Finding, Hit-to-Lead, Lead Optimization, Oncology, Small Molecules, Structural Biology, Tumor Models

VIEW

AACR 2023: Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma

In our latest AACR poster, WuXi AppTec scientists characterize the therapeutic potential of the antibody-drug conjugate (ADC) polatuzumab vedotin across a panel of established, in-house diffuse large B-cell lymphoma (DLBCL) patient-derived xenograft (PDX) models. Among our panel of lymphoma PDX models, three represent the germinal center B-cell (GCB) subtype. The authors show that 50% of …Read More >

Resource Type: Poster
Resource Topic: Antibody Drug Conjugate, Lead Optimization, Oncology, Tumor Models

VIEW

AACR 2023: A tailored platform enables BRAF-targeted drug discovery and precision medicine

In our latest AACR poster, WuXi AppTec scientists showcase the development of a tailored platform of patient-derived xenograft (PDX) models based on the classification of BRAF mutations. This panel covers all 3 classes of BRAF mutants, including subtypes for which viable therapeutic options remain limited. The authors demonstrate that these PDX models are responsive to …Read More >

Resource Type: Poster
Resource Topic: Lead Optimization, Oncology, Small Molecules, Tumor Models

VIEW

Discovery Newsletter: April 2023

In this month’s newsletter, learn more about our comprehensive panel of CDK4/6 inhibitor-resistant breast cancer models and in vitro imaging assays for compound profiling.  We also showcase our recent publications describing the development of HBV antigen inhibitors and noncovalent inhibitors of the SARS-CoV-2 3C-like protease (3CLpro).  

Resource Type: Latest Science, Newsletter
Resource Topic: Biochemical Assays, Biophysical Assays, Cell-based Assays, Hit-to-Lead, in vitro biology, Infectious Diseases, Lead Optimization, Oncology, Small Molecules, Structural Biology, Tumor Models

VIEW

BRAF-Related In Vivo Models

Discover our comprehensive platform of CDX and PDX tumor models, carrying BRAF mutations across multiple cancer types: 18 CDX models carrying BRAF mutation (V600E, G469A, G464V, G466V, G596R or N581Y), covering melanoma, breast cancer, lung cancer and colorectal cancer 18 PDX models carrying BRAF mutation (V600E, G469A, G469E, D594N or N581S), covering melanoma, pancreatic cancer, …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Lead Optimization, Oncology, Tumor Models

VIEW

Xenograft and Syngeneic Tumor Models in Rats

Leverage our extensive panel of rat xenograft and syngeneic tumor models. Advantages for using rats in preclinical efficacy studies compared with mice include: more similar metabolism and physiology to human; easier use for orthotopic model surgery, vascular manipulation, and imaging; larger sampling sizes to ensure sufficient amount for bioanalysis; consistent animal species to toxicology studies …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Candidate Selection, Oncology, Tumor Models

VIEW

Fluoroalkane modified cationic polymers for personalized mRNA cancer vaccines

Delivery carriers are a critical component in the development of mRNA vaccines. Here, we describe the synthesis of a cationic polymer as a carrier for mRNA cancer vaccine delivery. In vivo results show that this polymer-based mRNA vaccine significantly delays tumor growth after vaccination of mice. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9743697/  

Resource Type: Latest Science, Publication
Resource Topic: Oncology, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!